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Abstract 
Using the CMRP ‘bridge' μ+ probe, microdosimetric measurements were undertaken out-of-field using a 
therapeutic scanning proton pencil beam and in-field using a 12C ion therapy field. These measurements 
were undertaken at Mayo Clinic, Rochester, USA and at HIMAC, Chiba, Japan, respectively. For a typical 
proton field used in the treatment of deep-seated tumors, we observed dose-equivalent values ranging 
from 0.62 to 0.99 mSv/Gy at locations downstream of the distal edge. Lateral measurements at depths 
close to the entrance and along the SOBP plateau were found to reach maximum values of 3.1 mSv/Gy 
and 5.3 mSv/Gy at 10 mm from the field edge, respectively, and decreased to ~0.04 mSv/Gy 120 mm 
from the field edge. The ability to measure the dose-equivalent with high spatial resolution is particularly 
relevant to healthy tissue dose calculations in hadron therapy treatments. We have also shown 
qualitatively and quantitively the effects critical organ motion would have in treatment using 
microdosimetric spectra. Large differences in spectra and RBE10 were observed for treatments where 
miscalculations of 12C ion range would result in critical structures being irradiated, showing the 
importance of motion management. 
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MICRODOSIMETRIC APPLICATIONS IN PROTON AND HEAVY 
ION THERAPY USING SILICON MICRODOSIMETERS 
 
L. Chartier1, L. T. Tran1, D. Bolst1, S. Guatelli1, A. Pogossov1, D. A. Prokopovich1,2, M. I. Reinhard1,2, V. 
Perevertaylo3, S. Anderson4, C. Beltran4, N. Matsufuji5, M. Jackson1,6, and A. B. Rosenfeld1,* 
1Centre for Medical Radiation Physics, University of Wollongong, Wollongong, NSW, 2522, Australia 
2Ionising Radiation, Nuclear Stewardship Platform, NSTLI, ANSTO, Lucas Heights, NSW, 2234, Australia 
3SPA-BIT, Kiev, Ukraine 
4Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55902, USA 
5National Institute for Quantum and Radiological Science and Technology, Japan 
6School of Medicine, University of New South Wales, Kensington, NSW, 2052, Australia 
Using the CMRP “bridge”  probe, microdosimetric measurements were undertaken out-of-field using a therapeutic 
scanning proton pencil beam and in-field using a 12C ion therapy field. These measurements were undertaken at Mayo 
Clinic, Rochester, USA and at HIMAC, Chiba, Japan, respectively. For a typical proton field used in the treatment of 
deep-seated tumors, we observed dose-equivalent values ranging from 0.62-0.99 mSv/Gy at locations downstream of the 
distal edge. Lateral measurements at depths close to the entrance and along the SOBP plateau were found to reach 
maximum values of 3.1 mSv/Gy and 5.3 mSv/Gy at 10mm from the field edge, respectively, and decreased to 
approximately 0.04 mSv/Gy 120 mm from the field edge. The ability to measure the dose-equivalent with high spatial 
resolution is particularly relevant to healthy tissue dose calculations in hadron therapy treatments. We have also shown 
qualitatively and quantitively the effects critical organ motion would have in treatment using microdosimetric spectra. 
Large differences in spectra and RBE10 were observed for treatments where miscalculations of 
12C ion range would result 
in critical structures being irradiated, showing the importance of motion management. 
 
INTRODUCTION 
Delivery of dose to out-of-field healthy tissue is always 
detrimental to treatment outcome across all radiation 
therapy modalities, and naturally increases the risk of 
secondary malignancy, especially in children(1). The 
ions used in charged particle therapy undergo 
interactions with materials in the beam line, treatment 
head, beam-shaping devices and within the patient. 
Unlike most conventional photon therapies, these 
interactions are both electronic and nuclear in nature. 
While most processes are due to multiple Coulomb 
scattering, reactions with target nuclei can generate 
neutrons and fragments that will deliver excess dose to 
both target and non-target regions distally and laterally 
within a patient(2). Naturally, the absence of materials 
upstream of the patient reduces neutron and fragment 
production and is one of many reasons why particle 
therapy modalities are moving from passive scattering 
to active scanning techniques to deliver and shape the 
beam to the target(3,4). 
Many studies with protons have been undertaken to 
measure the out-of-field dose delivered to tissue 
external to the target volume(5-9), however due to 
differing measuring techniques, beam geometries, 
proton energies and acquisition locations, it is difficult 
to compare them directly. Furthermore, most 
measurements are taken around the room, far outside 
the patient which is not particularly relevant to 
treatment outcomes. Whilst there can be large 
differences in delivery systems and in-beam devices, 
most studies obtained similar dose-equivalent values up 
to the order of 10 mSv/Gy close to the field, and 
decreasing to minima of between 0.001 - 0.1 mSv/Gy 
at distances of 10-100 cm lateral to the field. Due to the 
absence of beam modifying materials, active scanning 
systems produce less neutrons and as a result, lower 
dose-equivalent values, however the extent to which 
this is true has been disputed in the past(10,11). 
One factor that can affect the dose delivered to the 
treatment volumes and out-of-field regions of the body 
is intra-fractional organ motion. This is true for all 
treatment types, however it is especially important in 
particle therapy due to increased relative biological 
effectiveness (RBE) at the Bragg peak caused by high 
LET particles. Respiratory motion is one type of 
motion that causes decreased treatment efficiency as it 
not only affects the ability to accurately treat lung 
cancer, it also causes other organs in the body to move 
from their predicted locations(12). This can cause large 
*Corresponding author: anatoly@uow.edu.au 
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errors in delivered dose to the tumor, healthy tissue and 
critical organs, especially if close to the Bragg peak. 
Whilst preliminary theoretical calculations and cell 
studies have been undertaken to investigate motion in 
particle therapy(13), the effect that organ motion has on 
particle spectra and the RBE needs further 
investigation, especially with advancing technology 
such as proton and 12C pencil beam scanning systems. 
One technique that can be utilized to evaluate both out-
of-field and in-field quality of mixed radiation fields is 
microdosimetry. It can be used for radiation protection 
purposes to calculate dosimetric quantities such as the 
out-of-field dose-equivalent, as well as the RBE in 
therapeutic fields, based on radiobiological models. 
Using the radiological modified microdosimetric 
kinetic model (MKM) and microdosimetric spectra(14), 
RBE10 can be derived,  defined as the ratio of the dose 
required to achieve 10% cell survival using X-rays to 
that required when using the radiation of interest. The 
fundamental quantity used in microdosimetry is the 
lineal energy , defined in equation 1, with units 
keV/ m(15). To measure lineal energy, a detector is 
required that can measure single energy deposition 
events of magnitude  and possess geometry with a 
well-known average chord length .̅  The dose-mean 
lineal energy  	, defined as the first moment of its 
dose-weighted distribution  (eqation 2), can be 
used to describe the field at a specific point using the 
distribution of lineal energy events . 
/ 	̅ (1) 
/  (2) 
Previous work with silicon microdosimeters has been 
undertaken by the CMRP to measure microdosimetric 
quantities in-field(16) and out-of-field(17, 18) in passively 
scattered proton fields, however studies have not been 
carried out using proton pencil beam scanning (PBS). 
This work demonstrates the usefulness of new silicon-
on-insulator (SOI) microdosimeters in assessing beam 
quality in proton PBS and 12C ion therapy systems. The 
dose-equivalent and other microdosimetric quantities 
have been determined in out-of-field locations using a 
spread-out Bragg peak proton PBS field at Mayo 
Clinic, Rochester, USA. We also present work 
undertaken at the Heavy Ion Medical Accelerator in 
Chiba (HIMAC), Japan to investigate the effect that 
motion has on microdosimetric spectra and RBE10 in a 
typical patient plan using passive beam delivery. 
METHODS 
SOI Bridge Microdosimeter 
The Bridge microdosimeter is a segmented SOI 
radiation detector containing 4248 PIN diodes, referred 
to as sensitive volumes (SVs). Each SV has an area of 
30  30 m2 and thickness 10 m in order approximate 
the size of mammalian cells. To prevent external 
charge collection to the SVs and improve its geometric 
definition, the silicon surrounding the diodes has been 
removed using plasma etching, leaving well-defined 
parallelepiped SVs with 20 x 15 x 10 m "bridges" that 
support the aluminium bus. The microdosimeter is 
packaged on an in-house designed front-end probe, 
known as the MicroPlus ( ) probe, created to 
minimize noise associated with leakage current and 
capacitance at the microdosimeters operating voltage 
(10V), seen in figure 1. The Bridge microdosimeter has 
been described and characterized in terms of its charge 
collection in previous works(17, 18). 
The  probe is placed in a waterproof PMMA sheath 
to protect the electronics and allow operation in a water 
phantom. Attached to the  probe is an in-house 
designed shaping amplifier which converts the 
preamplifier pulse to a Gaussian for processing by an 
Amptek multichannel analyzer (MCA). 
 
Figure 1.  probe with SEM image showing the Bridge 
Microdosimeter sensitive volumes. 
Phantom 
Previous studies have used a modular PMMA phantom 
to adjust the microdosimeter depth, however this setup 
is relatively inflexible due to the set thickness of 
PMMA slabs. To overcome this limitation, a relatively 
low-cost XY-stage was built using a MakerBot 
Replicator 3D-printer and PMMA water tank, 
controlled remotely using Arduino-driven stepper 
motors. Not only does such a system allow flexibility 
in controlling the depth and lateral position of the 
microdosimeter, it also facilitates custom movements, 
used in this study to simulate simple linear motion as 
well as lung motion. This is achieved by moving the 
depth and lateral position of the detector using 
predefined profiles.  
Out-of-field PBS measurements at Mayo Clinic 
Out-of-field measurements were undertaken to 
investigate radiation effects that would occur in healthy 
tissue surrounding a treatment volume. This was 
carried out at the proton therapy facility at Mayo Clinic 
Hospital, Rochester, MN, USA. This system employs 
intensity modulated PBS to deliver treatment without 
the use of patient-specific beam shaping devices. A 2.2 
Gy treatment was delivered as a 10 x 10 cm2 SOBP 
field with 6cm modulation between 40-100mm, created 
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uncertainty in depth and lateral position of the 
microdosimeter is at most 1 mm, based on the 
repeatability of movement and measurement of the 
initial microdosimeter position. There is an inherent 
uncertainty in the silicon-to-tissue conversion factor  
of approximately 2%.  
RESULTS 
Out-of-Field Measurements using Proton PBS 
Downstream of the SOBP 
Table. 1 presents the dose-mean lineal energy , 
average quality factor   and dose-equivalent  from 
acquisitions located downstream at depths of 110mm 
and 150mm, with corresponding microdosimetric 
spectra shown in figure 4. The generation of higher 
LET particles is seen to be more prevalent at 150 mm 
as can be seen by higher  and   values, however  
is lower, resulting in less dose delivered out-of-field 
from neutrons, per treatment Gy. In both spectra, high 
LET events above 100 keV/ m are most likely from 
alpha particles produced through (n, ) inelastic 
reactions within the silicon, carbon and oxygen. 
Despite these events, the spectra is mainly dominated 
by lower lineal energy events originating from recoil 
protons produced through elastic (n,p) reactions inside 
the water phantom. 
Table 1. Dose-mean lineal energy, average quality factor 
and dose-equivalent for downstream acquisitions 
Depth (mm)  (keV/ m)  H/Dose (mSv/Gy))
110  21.9  3.4 5.4  0.6 0.99  0.11 
150 27.2  5.7 6.1  0.9 0.62  0.09 
 
Figure 4. Microdosimetric spectra obtained at depths 110mm 
and 150mm in water. 
 
Lateral to the Field Edge 
Microdosimetric spectra produced from out-of-field 
acquisitions at each lateral location for depths 25 mm 
and 80 mm are shown in figure 5 and figure 6, 
respectively. For these acquisitions, the spectra is 
characterized by a low lineal energy peak with a higher 
lineal energy tail. For both depths, the microdosimetric 
spectra obtained at 10mm out-of-field spans a large 
range of lineal energies from approximately 0.7 
keV/ m to 70 keV/ m, produced by laterally scattered 
primary protons due to the relatively wide penumbra. 
At a depth of 80 mm in water, the microdosimetric 
spectrum for 10 mm out-of-field is naturally broader 
compared to that at 25 mm depth as the scattered 
protons have lower energy, and hence higher LET at 
greater depths. Moving further laterally from the field 
edge, at 30, 60 and 120 mm, the spectrum is dominated 
by recoil protons induced by neutrons and are 
extremely similar for both 25 mm and 80 mm depths. 
 
Figure 5. Microdosimetric spectra at 10, 30, 60 and 120 mm 
laterally out-of-field (OOF) at a depth of 25 mm in water. 
 
Figure 6. Microdosimetric spectra at 10, 30, 60 and 120 mm 
laterally out-of-field (OOF) at a depth of 80 mm in water. 
Figure 7 shows the  distributions for out-of-field 
positions at 25 mm and 80 mm depths in water. Despite 
the detector being located at significantly different 
parts along the SOBP profile (see figure 2), the  
distributions are extremely similar. At 10 mm from the 
field edge,   increases from approximately 5.8 
keV/ m and reaches a maximum of 7.5 and 7.8 
keV/ m for 25 mm and 80 mm depths, respectively, 
followed by a gradual fall-off with distance. Overall, 
for each lateral location, the  values at 80 mm depth 
5 
are greater than those at 25 mm depth by between 2 - 
7%, however agree within experimental error. 
The dose-equivalents for each set of out-of-field 
acquisitions at 25 mm and 80 mm depths are also 
presented in figure 7. Maximum values were measured 
at 10 mm from the field edge, reaching values of 3.1 
mSv/Gy and 5.3 mSv/Gy at depths 25 mm 80 mm, 
respectively. For perspective, a total treatment of 60Gy 
using this field would give a 300mSv dose-equivalent 
to a point of healthy tissue located 10 mm from the 
field edge. As expected, the dose-equivalent rapidly 
falls off with distance from the field edge, converging 
to approximately 0.04 mSv/Gy at 120 mm out-of-field 
for both depths.  
 
Figure 7. Lateral   and  distributions for out-of-field 
acquisitions at 25 mm and 80 mm depths. 
 
Figure 8. Comparison of simulated and experimental  
values for out-of-field acquisitions at 25 mm and 80 mm 
depths. 
Fig. 8 shows a comparison of the experimental and 
simulation results for 25mm and 80 mm depths. Good 
agreement between the experimental and simulation 
results was observed for 25 mm depth, however at 80 
mm, the simulated   values are slightly higher than 
the experimental results. This may be explained by a 
few high LET events which can significantly change 
the  value and can lead to substantial   
uncertainties.  
 
Motion Effects in Heavy Ion Therapy 
Figure 9 shows a comparison of the microdosimetric 
spectra when undergoing longitudinal lung motion. A 
significant difference was observed between the 
stationary spectra at 148mm (1 mm downstream of the 
distal edge) and when undergoing lung motion between 
141-149mm. When in motion, the edge of the 
hypothetical critical organ (represented by the 
microdosimeter) enters the highest LET region of the 
field, resulting in lineal energy events from carbon ions 
which dominate the spectra. In the stationary case, 
lower lineal energy events from neutron interactions 
dominate. From this observable change in field quality, 
there would be significantly more unplanned damage 
to the non-target volume in a clinical scenario. This is 
due to a significantly higher dose and increased   and 
RBE10 values, as seen in table 2. 
 
Figure 9. Microdosimetric spectra from stationary and moving 
acquisitions from depths 148mm, and undergoing lung motion 
from 141-149mm. 
 
Figure 10. Microdosimetric spectra from stationary and 
moving acquisitions at points A and B with the bolus (fig. 4). 
Figure 10 shows the microdosimetric spectra when the 
microdosimeter is stationary and when undergoing 
motion at points A and B (see figure 3) with 
corresponding   and RBE10 values shown in table 2. 
At both points, the  values when undergoing motion 
were greater the corresponding stationary 
measurement, showing a relative increase of 9.2% at 
point A and 13.6% at point B. When undergoing 
motion, the spectra in both cases shifts towards higher 
lineal energies due to the contribution of high LET 12C 
6 
ions stopping at the end of their range, towards the 
edge of the bolus. An increase in low lineal energy 
events was also observed when in motion from point B 
due to a higher contribution of fragments and neutrons 
produced from particle interactions further upstream. 
 
Table 2. Dose-mean lineal energy and RBE10 for all 
stationary and motion configurations 
Configuration  (keV/ m) RBE10 
Lung Motion  96.98  9.57 2.24  0.30 
Stationary 31.98  5.11 1.41  0.12 
Motion A 48.30  2.46 1.70  0.18 
Stationary A 44.22  2.32 1.64  0.16 
Motion B 84.34  6.90 2.03  0.25 
Stationary B 74.23  4.60 2.00  0.25 
 
CONCLUSIONS 
This work has demonstrated two specifics applications 
of the CMRP high spatial resolution “bridge”  probe 
in proton and 12C ion therapy. The small size of the  
probe with SOI microdosimeter has allowed 
measurements to be taken out-of-field, close to the 
field edge where critical organs may be in the body 
during treatment. Conventional detectors such as the 
tissue-equivalent proportional counter are too large to 
achieve this and are hence less relevant to predicting 
secondary cancer effects.  
 
Out-of-field measurements with the SOI 
microdosimeter in a proton PBS field have been carried 
out for the first time and revealed an interesting  
distribution laterally to the field at different depths. For 
both depths at 10 mm from the field edge, the 
microdosimetric spectra is dominated by laterally 
scattered primary protons from the nozzle, resulting in 
a relatively low . Moving further out between 30 
mm – 120 mm from the field edge,  increases due to 
the fast neutron contribution, followed by a gradual 
fall-off with distance. The measured  distributions at 
25 mm depth are in slightly better agreement with 
predicted Monte Carlo simulations than 80 mm depth 
due to possible lack of statistics that may effect neutron 
spectra and lead to slightly increased probability of 
Si(n, α) events. The dose-equivalent for proton PBS 
delivery systems shows significant differences to 
values obtained for fields delivered using non-scanning 
systems(9)  
 
The  probe with SOI “bridge” microdosimeter also 
proved to be useful for studying the effects of target 
motion in 12C ion therapy. Large differences in 
microdosimetric spectra and RBE10 were observed at 
stationary points and for motion along different kinds 
of trajectories. Obtained results show that this device is 
suitable for investigating interplay effects by 
mimicking organ motion due to its lightweight 
construction and the stable microphonic properties of 
the probe front-end. 
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